AI Summary
In this clinical update, Dr. Daniel Griffin discusses various topics related to the COVID-19 pandemic, including new virus strains from farmed fur animals, comparisons between mRNA and pox vectored vaccines, telehealth management of the disease, prophylactic treatments, and the effects of various treatments on outcomes. He also covers statistics on SARS-CoV-2 infections, viral load correlation with vaccination status, treatment options, and protocols for healthcare workers. Additionally, he explores long COVID and changes in microbiota due to SARS-CoV-2 infection during the Omicron variant period. The podcast episode provides detailed information and resources related to the ongoing pandemic.
In his weekly clinical update, Dr. Griffin dives into “pandemic potential” viruses isolated from farmed fur animals, how the mRNA and pox vectored vaccines against mpox spar against each other, how telehealth does managing mpox, and if prophylactic use of the anti-RSV monoclonal for infants is cost-effective before reviewing the recent statistics on SARS-CoV-2 infection, if viral load correlates to one vaccination status, where to find PEMGARDA, does administration of molnupiravir reduce symptoms in the vaccinated, when to use convalescent plasma, how molnupiravirs treatment leads to better outcomes 3 and 6 months after treatment, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, if vaccination against SARS-CoV-2 does protect against long COVID, and if SARS-CoV-2 during Omicron alters ones’ micriobiota.
Click arrow to play
Download TWiV 1148 (38 MB .mp3, 45 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Lending you the viruses in my fur (Nature)
- mRNA or vaccinia based mpox vaccine (Cell)
- Virtual outpatient management of mpox (OFID)
- NYC: mpox vaccination finder (NYC)
- Vaccine, mpox/COVID-19 near you (NYC)
- Expensive or not expensive anti-RSV monoclonal therapy for infants (American Academy of Pediatrics)
- COVID-19 deaths (CDC)
- COVID-19 national and regional trends (CDC)
- COVID-19 variant tracker (CDC)
- SARS-CoV-2 genomes galore (Nextstrain)
- Association of vaccination and SARS-CoV-2 viral load phase 3 (JID)
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
- Where to get pemgarda (Pemgarda)
- EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
- Early phase of SARs-CoV-2 infection (COVID.gov)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Drug interaction checker (University of Liverpool)
- Molnupiravir outcomes 3 and 6 months after treatment (LANCET Infectious Diseases)
- Antivirals and post-COVID-19 conditions (LANCET Infectious Disease)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- What to do when sick with a respiratory virus (CDC)
- When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids, dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Long COVID following infection with Omicron: oral microbiota changes(American Journal of Medicine)
- Letters read on TWiV 1148
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The post TWiV 1148: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.